Bristol-Myers Squibb Company

New York Stock Exchange
Back to all articles
Somewhat Bullish +45

Nykredit A S Purchases New Shares in Bristol Myers Squibb Company $BMY - MarketBeat

AI-generated analysis

📈 Nykredit A/S acquired a new position in BMY worth approximately $29.2 million during the second quarter.

💰 Bristol Myers Squibb reported quarterly EPS of $2.04, significantly beating analyst estimates of $1.60.

📈 Revenue increased 5.7% year-over-year to reach $12.97 billion in the latest quarter.

💸 The company pays a quarterly dividend of $0.63 per share, offering a 3.7% annualized yield.

🔬 Positive investor sentiment is supported by encouraging long-term data for Camzyos from the EXPLORER-LTE study.

⚠️ Bristol Myers Squibb paused enrollment in zola-cel autoimmune trials due to inflammatory side effects.

📉 The trial pause raises concerns about the risk profile of experimental cell therapy programs.

🔍 Novartis and BMY halted autoimmune trials following deaths or serious side effects, reinforcing safety concerns.

📊 Analysts rate BMY a 'Moderate Buy' with an average price target of $66.06.

🚀 Sanford C. Bernstein upgraded BMY from 'market perform' to 'outperform' in late August.

🔥 Raymond Financial initiated coverage with a 'strong-buy' rating on the stock.

⚖️ Piper Sandler initiated coverage assigning an 'overweight' rating to Bristol Myers Squibb shares.

📉 Jefferies Financial Group cut its rating from 'buy' to 'hold' in late August.

📈 The stock opened at $68.06, trading above its 50-day and 200-day moving averages.

🏢 Corporate insiders own a minimal 0.05% of the company's outstanding shares.

Bullish Signals
  • Bristol Myers Squibb reported quarterly EPS of $2.04, beating analyst estimates of $1.60 by $0.44.
  • Revenue rose 5.7% year-over-year to $12.97 billion, exceeding the consensus estimate of $11.74 billion.
  • Encouraging long-term data for Camzyos from the EXPLORER-LTE study supports renewed investor interest and growth expectations.
  • Institutional ownership remains strong at 76.41%, with Nykredit A/S adding a $29.2 million position in Q2.
  • Analysts have upgraded or initiated coverage with bullish ratings, including 'outperform' from Sanford C. Bernstein and 'strong-buy' from Raymond James.
  • The stock trades at a P/E ratio of 14.99 with a market capitalization of $139.03 billion, reflecting solid valuation metrics.
  • Analysts forecast FY 2026 EPS between 6.75 and 7.00, indicating continued growth expectations.
Risk Factors
  • Bristol Myers Squibb voluntarily paused enrollment in zola-cel autoimmune trials after inflammatory side effects emerged.
  • The trial pause raises concerns about the therapy's risk profile and may delay a potentially important pipeline program.
  • Broader reporting that Novartis and BMY halted autoimmune trials following deaths or serious side effects reinforces safety concerns.
  • RBC Capital maintained a 'Hold' rating, noting that the stock's strong run may already incorporate much of the favorable news.
  • Corporate insider SVP Phil M. Holzer sold 500 shares in late August, representing a 2.88% decrease in his position.
Full Analysis
Nykredit A/S purchased 506,199 shares of Bristol Myers Squibb (BMY) in the second quarter, valued at approximately $29.2 million, contributing to institutional ownership of 76.41%. The company reported strong quarterly financials with earnings per share of $2.04, beating estimates of $1.60, and revenue rising 5.7% year-over-year to $12.97 billion. Bristol Myers Squibb maintains a quarterly dividend of $0.63 per share, yielding 3.7%, while analysts hold a consensus 'Moderate Buy' rating with an average price target of $66.06. Recent positive sentiment is driven by encouraging long-term data for the heart-failure drug Camzyos from the EXPLORER-LTE study, which supports its growth trajectory. However, the company faces pipeline risks as it voluntarily paused enrollment in zola-cel autoimmune cell-therapy trials due to inflammatory side effects. This pause raises concerns about the safety profile of experimental therapies and may increase scrutiny on trial-disclosure practices, particularly following similar halts by Novartis. Analyst sentiment remains mixed with recent rating changes: Sanford C. Bernstein upgraded BMY to 'outperform,' Raymond James initiated a 'strong-buy' rating, and Piper Sandler assigned an 'overweight' rating, while Jefferies cut its rating to 'hold.' The stock trades at a P/E ratio of 14.99 with a market capitalization of $139.03 billion.